Compare D R Horton Inc (DHI) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Gilead Sciences, Inc. — how do they compare? D R Horton Inc trades at $149.65 (market cap $40.79B), while Gilead Sciences, Inc. trades at $138.44 (market cap $168.47B). The key difference: Gilead Sciences, Inc. is far larger — about 4.1× D R Horton Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| DHI | GILD | |
|---|---|---|
Market Cap | $40.79B | $168.47B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $155.80 |
52-Week Low | $132.53 | $110.56 |
Enterprise Value | $45.89B | $191.54B |
Dividend Yield | 1.23% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $149.88, down 0.6% on the day, with a bearish technical signal from moving averages and a neutral RSI. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year guidance amid weak homebuying demand. Valuation metrics appear reasonable with a P/E of 13.9 and P/S of 1.27. Recent news highlights management's focus on cost control and inventory discipline to offset market challenges.
The outlook is mixed; strong cash flow and execution provide support, but elevated mortgage rates and sluggish demand pose headwinds. Analyst consensus leans neutral with a $153 price target. Key risks include margin pressure and macroeconomic sensitivity, while the dividend offers income stability.
Gilead Sciences (GILD) trades at $138.14, up 1.75% in the last session, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong Q2 2026 revenue growth of 8% year-over-year, driven by HIV drug sales, though a net loss of $6.75 per share resulted from acquisition-related charges. Analyst consensus is strongly bullish with a $151.22 price target, while institutional activity shows mixed positioning adjustments.
The outlook for GILD is positive due to robust HIV franchise performance and raised 2026 guidance, but risks include patent cliffs by the mid-2030s and integration costs from acquisitions. The stock offers potential upside from pipeline advancements, though volatility may persist from earnings fluctuations and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
